



Live outside of Pain

INVESTOR PRESENTATION

Q1 2026

steve@nextmedtech.com

nextmedtech.com



Current pain treatments do not treat the source of pain!
Chronic pain is experienced by 85 million Americans and 100 million Europeans.
17 million Americans suffer high impact pain limiting work and normal life.

THE PERFECT SOLUTION



Chronic pain can afflict anyone. The perfect solution is one that does not have side effects or addiction. A solution that people suffering chronic pain could use at home without visits to the clinic. The solution would also promote healing of the source of the pain.

Solution - BIO energy Medicine



I-LOOP

No other technologies like I LOOP, or even similar to it is known to exist.

I LOOP is Bio-energy medical a device developed by Nexxt Medtech.,This device is capable of restoring the body's natural electrical energy. I LOOP conditions the energy for acceptance by the body, through its biofeedback capability the result of this energy frequency and the software algorithms then determine which frequency the body requires next. This results in the body's electrical energy levels achieving peak levels. When our body is at peak energy, this is called Redox Equilibrium, which then enables the elimination of inflammation and cellular regeneration. In other word's the pain is gone and the area of pain begins to heal. This is in effect promoting healing rather than blocking the pain signal.

The Nexxt Medtech Solution



Total addressable market

Acute pain afflicts 185 million people in the US and European Union. In the EU there are 20 million people with high impact pain and 17 million in the US. These 37 million people are most in need but the whole market will be addressed.

If we convert 20% of high impact patients as users we would have 7.4 million users at \$400 per year for app subscription our annual revenue would be just under 3 billion dollars. Our margins will be over 50%. While it is easy to see a much larger market it is also clear that this investment will deliver exceptional returns on a small market penetration.

I LOOP

- The I LOOP is a small device worn on the waist that connects to any smart phone by blue tooth. The smart phone app drives the I LOOP which has electrodes connected to the feet and hands delivering the necessary electrical connection.
- The I LOOP sells for \$3,000
- The I LOOP app is a subscription for \$400 annually
- Rental of the combination is \$300 monthly initially for the first 3 months and \$200 monthly thereafter. Transition to ownership offers a discount.

I LOOP

Devices will be promoted in multiple channels:

Physical therapy clinics are treating people with pain daily. There are 38k PT clinics in the US alone, employing 210K physical therapists and 620k physical therapists are employed in the EU. We have clinics waiting for units.

Chiropractors and massage therapist also treat many people with pain and will also be a channel to introduce the **I LOOP**

There is a large community of older people, who suffer chronic pain more frequently, living in retirement communities and independent living homes. We will send in a direct sales team to present and demonstrate to these communities.

Direct marketing via Meta advertising and US Post direct mail will be supported by phone and a sales team.

Clinical Device

The development of our clinical device provided proof that the technology works. It also became clear to us that we needed to drive the use to the individual patient in order for them to be able to use it more often and to drive the cost drastically down. The new device will be an App on the phone with the software in the cloud. The current generator/biofeedback device will be worn on the waist with connections to socks and gloves which will be the electrodes transmitting the energy through the hands and feet.



The lifetime value of the device is demonstrated by:

The lifetime value of the device is demonstrated by:

Clinical trials showing **97% efficacy**.

Chronic pain is normally degenerative and most patients need the device for life

Use of the clinical device has demonstrated to us that we need the home use device

Home use device will allow frequent use

New device will be low cost to operate meaning long term use without financial burden.

Clinical trials have shown high efficacy across multiple studies. (see www.nexxtmedtech.com)

Margins

The Device production cost will be \$500 initially, as production increases cost will decrease.

Device will retail at \$3,000 and will be commissionable at 25% so the margin will be \$1,750 per unit. This translates to \$1,750 margin per device sale.

App use will be by subscription @\$400 per year. Operating cost for cloud space and maintenance of the app is \$20 per user and \$40 sales commission. This results in a margin of \$340 annually.

Patients requiring short term use of the device may rent the device at \$300 per month for the first three months and \$200 per month thereafter.

Projections Based on 4,000 devices in year two and 9,000 in year three



	Year 1	Year 2	Year 3
Revenue	-	\$ 5,674,379	\$ 32,058,729
COGS	-	\$ 3,345,051	\$ 7,637,982
Design/engineering	\$ 1,607,500	\$ 152,500	-
Marketing	\$ 45,000	\$ 606,849	\$ 1,195,433
Operating Expense	\$ 326,500	\$ 1,359,717	\$ 3,991,354
General & Administration	\$ 60,000	\$ 243,000	\$ 247,200
Profit	\$ (-2,039,000)	\$ (32,738)	\$ 18,986,761

GOALS	Design, Engineer & Certify Device	Deliver 4000 Device	Deliver 9000 Device
-------	-----------------------------------	---------------------	---------------------

Deal summary



Nexxt Medtech is selling 200,000 shares at \$20 each
with a minimum sale of 1,250 shares per

Qualified Investor

The founders have 125,000 shares each.

The company is registered with the SEC under 506 (d).



Nexxt Medtech Inc
427 Wright Street #205,
Lakewood, Colorado 80228

Steven Jacobs
CHIEF EXECUTIVE OFFICER



+1 (303) 834-2789



steve@nexxtmedtech.com



linkedin.com/in/steve-jacobs-gold-shield/



nexxtmedtech.com

Claudio Tassi
CHIEF SCIENCE OFFICER



claudio@nexxtmedtech.com